---
figid: PMC4086757__cmr-24-408-g003
figtitle: Classification of resistance mechanisms to BRAF inhibitors
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Diaporthe sclerotioides
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC4086757
filename: cmr-24-408-g003.jpg
figlink: /pmc/articles/PMC4086757/figure/F1/
number: F1
caption: Classification of resistance mechanisms to BRAF inhibitors. The figure shows
  a classification system for both de-novo and acquired resistance mechanisms to the
  selective BRAF inhibitors relative to the BRAF mutation. Such resistance mechanisms
  may lie upstream, downstream or at the same level along the mitogen-activated protein
  kinase pathway, or act through a bypass signalling pathway. AKT, protein kinase
  B; BRAF, v-raf murine sarcoma viral oncogene homologue B1; COT, P MAP3K8/mitogen-activated
  protein kinase kinase kinase 8; ERK, extracellular signal-regulated kinase; GCN,
  gene copy number; IGF-1R, insulin-like growth factor 1 receptor; MEK, mitogen-activated
  protein kinase kinase; mTOR, mammalian target of rapamycin; NRAS, neuroblastoma
  RAS viral oncogene homologue; PDGFR-β, platelet-derived growth factor receptor β;
  PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homologue; RAS, rat
  sarcoma; RTK, receptor tyrosine kinase. Modified from Lemech et al. .
papertitle: Resistance surveillance in a BRAF mutant melanoma patient on long-term
  BRAF-inhibitor treatment.
reftext: Gabriel Mak, et al. Melanoma Res. 2014 Aug;24(4):408-412.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8644968
figid_alias: PMC4086757__F1
figtype: Figure
redirect_from: /figures/PMC4086757__F1
ndex: 8a1cfd94-df1e-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4086757__cmr-24-408-g003.html
  '@type': Dataset
  description: Classification of resistance mechanisms to BRAF inhibitors. The figure
    shows a classification system for both de-novo and acquired resistance mechanisms
    to the selective BRAF inhibitors relative to the BRAF mutation. Such resistance
    mechanisms may lie upstream, downstream or at the same level along the mitogen-activated
    protein kinase pathway, or act through a bypass signalling pathway. AKT, protein
    kinase B; BRAF, v-raf murine sarcoma viral oncogene homologue B1; COT, P MAP3K8/mitogen-activated
    protein kinase kinase kinase 8; ERK, extracellular signal-regulated kinase; GCN,
    gene copy number; IGF-1R, insulin-like growth factor 1 receptor; MEK, mitogen-activated
    protein kinase kinase; mTOR, mammalian target of rapamycin; NRAS, neuroblastoma
    RAS viral oncogene homologue; PDGFR-β, platelet-derived growth factor receptor
    β; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homologue; RAS,
    rat sarcoma; RTK, receptor tyrosine kinase. Modified from Lemech et al. .
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Igf1r
  - Pdgfrb
  - Nras
  - ras
  - Hras
  - Kras
  - Rem1
  - Braf
  - Braf-rs1
  - Pten
  - Map3k8
  - Raf1
  - Mdk
  - Akt1
  - Ephb2
  - Mapk1
  - Mtor
  - Cdk4
  - IGF1R
  - PDGFRB
  - NRAS
  - KRAS
  - HRAS
  - BRAF
  - PTEN
  - MAP3K8
  - CROT
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - CDK4
  - Th
  - Ephb1
  - Ccne1
  - Defb1
  - Ras64B
  - Ras85D
  - gbb
  - bgcn
  - mir-ban
  - Dsor1
  - Mtk
  - Akt
  - Erk7
  - rl
  - Tor
  - CycE
  - cyc
  - pdgfrb
  - nras
  - rab1ab
  - braf
  - si:dkey-222f8.3
  - ptenb
  - raf1a
  - mtor
  - cdk4
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
